Equity Profile

LGND

Ligand Pharmaceuticals Incorporated

Health CarePharmaceuticals$6.2B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ligand Pharmaceuticals Incorporated (LGND) is a healthcare company focused on developing and commercializing technologies that assist in the creation of new medicines. With a market cap of $6 billion, Ligand plays a significant role in the pharmaceutical industry, particularly in drug development and licensing.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Ligand has performed compared to previous quarters.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's expansion and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LGND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

In Q1-2026, Ligand reported an EPS of $1.63, significantly beating estimates by 66.84%. However, the stock dropped 9.55% the following day, indicating market concerns despite the strong earnings.

Management Promises & Guidance

Focus on expanding partnerships and licensing agreements.
Commitment to increasing R&D spending to enhance product development.
Plans to provide more detailed revenue guidance in future calls.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Ligand has consistently beaten EPS estimates, but the stock's reaction has been volatile. Investors will be keen to see if this trend continues.

Bull Case

If Ligand maintains its strong EPS performance and provides positive guidance, it could lead to a significant stock rally, given the historical trend of positive reactions to earnings beats.

Bear Case

Conversely, if Ligand fails to meet expectations or provides cautious guidance, it could lead to a sharp decline in stock price, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Ligand's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.

How much will R&D investment increase this quarter?

Investors will closely monitor R&D spending as it directly impacts future product development and revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Ligand's ability to maintain its earnings momentum due to its strong historical performance and recent R&D commitments.

Supporting Evidence

Ligand has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent insider buying could signal confidence in the company's future prospects.

Key Risk

If R&D spending significantly increases without a corresponding rise in revenue, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Ligand's ability to sustain its earnings momentum amidst increasing R&D investments.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±15.86%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

47.7%

Calls (100)P/C Ratio: 0.15Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests the stock could rise by about 1.84% on the first day, confirming the positive trend.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see a muted reaction, reflecting uncertainty.

Miss

Should Ligand miss expectations, history suggests a potential decline of around 2.94%, which could raise concerns about future performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new partnerships or licensing agreements.
2Details on R&D investment plans and expected outcomes.
3Insights into market demand for Ligand's products.
4Management's outlook on future revenue growth.
5Responses to analyst questions regarding recent stock performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Ligand has performed compared to previous quarters.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's expansion and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LGND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

In Q1-2026, Ligand reported an EPS of $1.63, significantly beating estimates by 66.84%. However, the stock dropped 9.55% the following day, indicating market concerns despite the strong earnings.

Management Promises & Guidance

Focus on expanding partnerships and licensing agreements.
Commitment to increasing R&D spending to enhance product development.
Plans to provide more detailed revenue guidance in future calls.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Ligand has consistently beaten EPS estimates, but the stock's reaction has been volatile. Investors will be keen to see if this trend continues.

Bull Case

If Ligand maintains its strong EPS performance and provides positive guidance, it could lead to a significant stock rally, given the historical trend of positive reactions to earnings beats.

Bear Case

Conversely, if Ligand fails to meet expectations or provides cautious guidance, it could lead to a sharp decline in stock price, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Ligand's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.

How much will R&D investment increase this quarter?

Investors will closely monitor R&D spending as it directly impacts future product development and revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Ligand's ability to maintain its earnings momentum due to its strong historical performance and recent R&D commitments.

Supporting Evidence

Ligand has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent insider buying could signal confidence in the company's future prospects.

Key Risk

If R&D spending significantly increases without a corresponding rise in revenue, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Ligand's ability to sustain its earnings momentum amidst increasing R&D investments.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±15.86%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

47.7%

Calls (100)P/C Ratio: 0.15Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests the stock could rise by about 1.84% on the first day, confirming the positive trend.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see a muted reaction, reflecting uncertainty.

Miss

Should Ligand miss expectations, history suggests a potential decline of around 2.94%, which could raise concerns about future performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new partnerships or licensing agreements.
2Details on R&D investment plans and expected outcomes.
3Insights into market demand for Ligand's products.
4Management's outlook on future revenue growth.
5Responses to analyst questions regarding recent stock performance.